There are many challenges China’s health care system is facing during the pandemic, but drug developers and tech firms are among the forces fighting the country’s worst public health crisis in two decades.
In the first of a five-part series on China’s healthcare system, Peggy Sito outlines the challenges facing the system worth US$2.3 trillion by 2030 in the most populous nation, as it finds itself at the epicentre of a second coronavirus outbreak in two decades.
In the second of a five-part series on China’s health care system, Eric Ng looks at how technological innovations – smartphone applications, 5G, big data, artificial intelligence – are coming together to help in the battle with the country’s worst public health crisis in two decades.
In the third of a five-part series on China’s health care system, Eric Ng looks at how a new breed of Chinese drug developers, armed with innovative treatments ranging from cancer to Alzheimer’s, has taken the lead to find a cure for the coronavirus pandemic ravaging the world.
In the fourth in a five-part series, Enoch Yiu looks how technology firms like Ant Financial and Tencent Holdings are using their innovative powers to create insurtech and mutual aid platforms that make health care coverage affordable to more people.
In the last of a five-part series, Peggy Sito considers the impact Beijing’s intervention against Covid-19 – in Wuhan and elsewhere – will have on its health care policies in the longer term.